Slides
Page 1
1 29 November 2023 2025 Annual General Meeting 17 November 2025 2025 Annual General Meeting 17 November 2025 For personal use only
Page 2
2 2 2025 Annual General Meeting AGENDA 1. Chair Address 2. CEO Presentation 3. Q&A / Voting Procedure Overview 4. Formal Business of the Meeting 5. General QuestionsFor personal use only
Page 3
3 29 November 2023 2025 Annual General Meeting Chair Address – Caroline Waldron 2025 Annual General Meeting 17 November 2025 3 For personal use only
Page 4
4 29 November 2023 2025 Annual General Meeting CEO Presentation – Allison Rossiter 2025 Annual General Meeting 17 November 2025 4 For personal use only
Page 5
“I would have loved access to a PCR test like this” 2025 Annual General Meeting 17 November 2025Patient Case Study – misdiagnosed Giardia Watch Online → Watch Online →For personal use only
Page 6
6 Blackpool Case Study – Easyscreen Implementation Challenge: Gastroenteritis diagnosis was slow, fragmented, and often inconclusive. 2025 Annual General Meeting 17 November 2025 6 Solution: Adopted EasyScreen Pan-Enteric Detection Kit for all inpatient and community stool samples. Results: • Rapid Results - 100% A&E cases had results within 5 hours • Better Care- Reduced unnecessary treatments, targeted antibiotic use • Broader Detection - Identified rare pathogens previously missed Impact: Faster, more accurate diagnosis and stronger infection control. For personal use only
Page 7
7 Who we are and what we do Who We Are Genetic Signatures is an Australian ASX-listed molecular diagnostics company, specialising in high-throughput syndromic PCR testing for detecting infectious diseases, helping to diagnose earlier, keeping people healthier. 2025 Annual General Meeting 17 November 2025 What We Do We develop and commercialise rapid, high-throughput PCR tests, powered by our proprietary 3base® technology that streamlines DNA analysis for faster, more accurate results. We focus on syndromic testing, which is the detection of multiple pathogens that cause similar symptoms in just one single test. Where We Operate • Headquartered in Sydney, Australia • Sales and field service teams in Australia, EMEA and United States • Channel partners in EMEA & Canada For personal use only
Page 8
8 What is 3base® technology DNA carries a genetic code consisting of 4 chemical bases. 3base® is the chemical conversion of cytosine (C) bases into thymine (T) resulting in the conversion of a native 4-base sequence into a 3-base sequence. 2025 Annual General Meeting 17 November 2025 C G T A G A C C T C A C T T C C A G G A C T G G C T G T A G A T T T T A T T T T T A G G A T T G G T The 4-base genetic sequence (CGTA) is converted to a 3-base sequence (GTA) for a genetic sequence of 10 bases. Reduces the complexity of the genetic code for reliable diagnosis Enables efficient pan- screening capabilities for a wide range of infectious diseases Enables greater resilience to genetic variation Universal sample extraction process regardless of sample type, compatible with DNA & RNA 1,048,576 combinations with 4-base 59,049 combinations with 3base® Allows for harmonised multiplexed PCR amplification conditions, improving cost efficiency 4-base 3-base For personal use only
Page 9
9 2025 - A year of transition 2025 Annual General Meeting 17 November 2025 On market portfolio review Appointment of new CEO, Allison Rossiter • New Instrument Strategy agreed • First US customer signed Appointment of ANZ Sales Leader, Sarah Peaty New strategic plan implemented • US leadership change • EMEA consolidation • Australian reorganisation JULY AUGUST SEPTEMBER OCTOBER FEBRUARY JANUARY DECEMBER NOVEMBER MARCH APRIL MAY JUNE Transition of Chair to Caroline Waldron Appointment of Anne Lockwood & Jenny Harry as Non-Executive Directors 2024 2025 For personal use only
Page 10
10 Approved products in key markets 2025 Annual General Meeting 17 November 2025 Respiratory Enteric Viral Bacterial Viral Bacterial Parasite For personal use only
Page 11
11 Progress in key markets in FY25 2025 Annual General Meeting 17 November 2025 • FY25 revenue increased 66% to $14.4m, delivering standout year on year growth • Strong respiratory sales powered across all quarters • Partnered with leading Australian pathology providers to scale testing capacity to meet winter demand peaks • FY25 EMEA revenue up 40% to $1.5m fueled by surging demand for enteric products and strong regional execution • Enteric sales focus pays off with 208% year-on-year growth • NHS trusts in the UK adopt our tests boosting infection control and preventing outbreaks in high- demand hospital wards • Streamlined EMEA operations, concentrating resources in core markets • Expanded go-to-market strategy, engaging stakeholders – from patients to payers • US operations strengthened with strategic leadership hires and team changes boost performance • Sales pipeline progressing, with steady advancement • First US commercial contracts secured, marking a pivotal milestone For personal use only
Page 12
12 New Strategic Direction – Automation Solution 2025 Annual General Meeting 17 November 2025 Lower development costs Faster development timelines Enhanced automation A Well-Considered Strategic Pivot • Secures the most commercially viable path forward Fresh Market Assessments • Identified priority syndromic infectious disease areas • Findings will inform and direct our future focus For personal use only
Page 13
13 Focus on delivering results in FY26 • Q1 FY26 sales of $5.4 million, representing an increase of 20%, over the previous quarter and a 15% uplift compared to the prior corresponding period; • Quarterly revenue result is the highest since COVID years; • Revenue contribution from all three regions with Australia gaining new business from existing customers, EMEA experiencing a 52% increase in Gastrointestinal (GI) testing and US receiving the first commercial order; • Second US contract was signed with an integrated healthcare organisation, marking a key milestone in the US commercial expansion. The first shipment of test kits was delivered in September, with testing expected to commence early in Q2 FY26; • A third US contract with previous customer experience site signed after the close of the quarter; • Strong balance sheet with $28.2m in cash and term deposits as at 30 September 2025. 2025 Annual General Meeting 17 November 2025 For personal use only
Page 14
14 Strategic priorities for FY26 2025 Annual General Meeting 17 November 2025 Building for the Future Development of new automated solution and state of the art software. Develop a menu to address emerging diseases where 3base® technology can shine. Further enhancements and improvements to workflows for on- market products. Unlock UK Opportunities Engage NHS leaders to prioritise infection control and outbreak prevention, signing at least 4 new accounts. Leverage data to highlight the health economic benefits of implementing the GSS Enteric tests. Enhance distributor partnerships in non- direct markets to drive expansion and capture new opportunities. Expanded Go-To-Market Strategy Concentrate commercial efforts on four high-priority U.S. states to maximise market penetration. Deepen partnerships with KOLs to elevate visibility and credibility of the molecular GI Parasite test. Laser focused social media campaigns targeting laboratories, clinicians and patients with GI symptoms to drive engagement and test demand. For personal use only
Page 15
15 Formal Business of the MeetingFor personal use only
Page 16
16 Q&A / Voting Procedure Overview 16 For personal use only
Page 17
17 2025 Annual General Meeting 17 November 2025 Consideration of Reports “To receive and consider the Financial Report, the Directors’ Report and the Independent Auditor’s Report of the Company for the financial year ended 30 June 2025 (Report).” No resolution is required for this item. Following consideration of the Reports, the Chair of the Meeting will give Shareholders a reasonable opportunity to ask questions and make comments on the Report. The Auditors are also present to answer any questions in relation to the Audit. For personal use only
Page 18
18 2025 Annual General Meeting 17 November 2025 Resolution 1 – Re-election of Director – Dr Neil Gunn To consider and, if thought fit, pass the following as an ordinary resolution: “That, Dr Neil Gunn who retires in accordance with clause 6.7 of the Company’s Constitution, having offered himself for election and being eligible, is re-elected as a Director of the Company.” FOR AGAINST OPEN Number of Shares 95,186,991 10,532,572 289,179 % of Proxies 89.79% 9.94% 0.27% Further Information • The Board (with Dr Gunn abstaining) recommends that Shareholders vote in FAVOUR of this resolution. • The Chair of the Meeting intends to vote undirected proxies in FAVOUR of this resolution. For personal use only
Page 19
19 2025 Annual General Meeting 17 November 2025 Resolution 2 – Re-election of Director – Ms Caroline Waldron To consider and, if thought fit, pass the following as an ordinary resolution: “That, Ms Caroline Waldron who retires in accordance with clause 6.7 of the Company’s Constitution, having offered herself for election and being eligible, is re-elected as a Director of the Company.” Further Information • The Board (with Ms Waldron abstaining) recommends that Shareholders vote in FAVOUR of this resolution. • The Chair of the Meeting intends to vote undirected proxies in FAVOUR of this resolution. FOR AGAINST OPEN Number of Shares 96,306,561 9,943,807 289,179 % of Proxies 90.40% 9.33% 0.27% For personal use only
Page 20
20 2025 Annual General Meeting 17 November 2025 Resolution 3 – Adoption of the Remuneration Report To consider and, if thought fit, pass the following as an ordinary resolution: “That, the Company’s Remuneration Report for the financial year ended 30 June 2025, as set out in the Directors’ Report, is adopted.” FOR AGAINST OPEN Number of Shares 91,683,737 11,553,875 282,276 % of Proxies 88.57% 11.16% 0.27% Further Information • Voting restrictions apply to KMP and their closely related parties. • The vote on this resolution is advisory only and does not bind the Directors or Company. • The Chair of the Meeting intends to vote undirected proxies in FAVOUR of this resolution. For personal use only
Page 21
21 2025 Annual General Meeting 17 November 2025 Resolution 4 – Approval to Grant Restricted Rights to a Director, Ms Anne Lockwood To consider and, if thought fit, pass the following as an ordinary resolution: “That, for the purposes of ASX Listing Rule 10.14, and for all other purposes, the issue of 250,000 Restricted Rights under the Genetic Signatures Rights Plan to Ms Anne Lockwood, the terms of which are set out in the Explanatory Memorandum accompanying this Notice, is approved.” FOR AGAINST OPEN Number of Shares 93,628,452 12,626,585 282,276 % of Proxies 87.89% 11.85% 0.26% Further Information • The Board (with Ms Lockwood abstaining) recommends that Shareholders vote in FAVOUR of this resolution. • The Chair of the Meeting intends to vote undirected proxies in FAVOUR of this resolution. For personal use only
Page 22
22 2025 Annual General Meeting 17 November 2025 Resolution 5 – Approval to Grant Restricted Rights to a Director, Dr Jenny Harry To consider and, if thought fit, pass the following as an ordinary resolution: “That, for the purposes of ASX Listing Rule 10.14, and for all other purposes, the issue of 250,000 Restricted Rights under the Genetic Signatures Rights Plan to Dr Jenny Harry, the terms of which are set out in the Explanatory Memorandum accompanying this Notice, is approved.” FOR AGAINST OPEN Number of Shares 93,628,452 12,626,585 282,276 % of Proxies 87.89% 11.85% 0.26% Further Information • The Board (with Dr Harry abstaining) recommends that Shareholders vote in FAVOUR of this resolution. • The Chair of the Meeting intends to vote undirected proxies in FAVOUR of this resolution. For personal use only
Page 23
23 General Questions 23 For personal use only
Page 24
24 24 Thank you for your attendanceFor personal use only
Page 25
25 Contact Us Allison Rossiter Chief Executive Officer E: allison.rossiter@geneticsignatures.com P: +61 (02) 9870 7580 Visit us www.geneticsignatures.com Follow us Karl Pechmann Chief Financial & Operating Officer & Joint Company Secretary E: karl.pechmann@geneticsignatures.com 25 For personal use only
Page 26
26 Disclaimer 2025 Annual General Meeting 17 November 2025 This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It provides general background information about the Company’s activities current as at the date of this presentation. This presentation is proprietary to GSS. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without express consent of GSS. No representation or warranty, express or implied, is or will be made in relation to, and no responsibility or liability (whether for negligence, under statute or otherwise) is or will be accepted by the Company or by any of its officers, directors, shareholders, employees or advisers as to or in relation to the accuracy or completeness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or any omission from this presentation or of any other written or oral information or opinions provided now or in the future to any interested party or its advisers. In particular, no representation or warranty is given as to the achievement or reasonableness of any plans, future projections, management targets, prospects or returns and nothing in this presentation is or should be relied upon as a promise or representation as to the future. The Company expressly disclaims all liability for any loss or damage of whatsoever kind (whether foreseeable or not) which may arise from any person acting on any information and opinions relating to the Company contained in this presentation or any information which is made available in connection with any further enquiries, notwithstanding any negligence, default or lack of care. In furnishing this presentation, the Company undertakes no obligation to provide any additional information. Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, the Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in these materials to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of the Company since the date of the presentation. This presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any or contract or investment decision. This presentation may not be released to US wire services or distributed in the United States. Without limiting the foregoing, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or in other jurisdictions where it would be illegal. The securities of Genetic Signatures have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (Securities Act) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and any other applicable US state securities laws or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable US state securities laws. The receipt of this presentation by any person and any information contained herein or subsequently communicated to any person is not to be taken as constituting the giving of investment advice by the Company or any other person to any such person. No such person should expect the Company or any of its officers, directors, shareholders, employees or advisers to owe it any duties or responsibilities and should take its own professional advice. The Recipient must rely solely on its own knowledge, investigation, judgement and assessment of the matters which are the subject of this presentation and to satisfy itself as to the accuracy and completeness. 26 For personal use only